Drug Discovery

Blue Oak, PsychoGenics enter into drug discovery partnership

Blue Oak Pharmaceuticals and PGI Drug Discovery (PsychoGenics) have entered into a partnership to discover and optimize novel treatments for brain disorders and psychiatric conditions.

Astellas Pharma acquires Mitobridge for $225m

Astellas Pharma has exercised its exclusive option right to acquire Mitobridge under the amended terms of the October 2013 partnership agreement governing their research and development (R&D) collaboration focused on discovering and developing novel drugs that target mitochondrial function.

I-Mab Biopharma partners with MorphoSys on cancer investigational medicine

I-Mab Biopharma and MorphoSys have entered into an exclusive regional licensing agreement to develop and commercialize MOR202 in China, Taiwan, Hong Kong and Macao.

resTORbio raises $40m from biotech and institutional investors

resTORbio, a clinical-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of aging-related diseases, has raised $40m in a Series B financing round.

Biogen, Alkermes to develop and commercialize ALKS 8700 to treat multiple sclerosis

Biogen and Alkermes have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral, monomethyl fumarate (MMF) small drug molecule in phase 3 development for the treatment of relapsing forms of multiple sclerosis (MS).

Research finds gastric acid suppressant lansoprazole could target tuberculosis

A new research in the UK suggests that a cheap and commonly used drug to treat heartburn, gastritis and ulcers has the potential to target Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB).

Hemogenyx, University of Oxford partner to transform blood cancers treatment

Hemogenyx Pharmaceuticals has partnered the University of Oxford to test new means of accelerating and improving the process by which transplanted blood stem cells grow and make healthy blood cells.

Canadian researchers discover medication to treat amyotrophic lateral sclerosis

Canadian researchers have discovered an effective medication for the treatment of individuals with amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease.

Inozyme Pharma secures $49m funding for rare disease therapies

Inozyme Pharma, which is developing novel medicines to treat rare diseases of calcification, affecting soft tissues and bone, has raised a $49m Series A financing.